Saturday, January 25, 2014
Monday, January 20, 2014
Medscape link: http://www.medscape.com/viewarticle/819366
January 17, 2014
A combination of 10 Chinese medicinal herbs in a capsule, known as Tianqi, reduced progression to type 2 diabetes in people with impaired glucose tolerance (IGT) in a randomized controlled trial in China.
This is the first study to show that a Chinese herbal medicine can "reduce the progression of prediabetes to diabetes," says study author Chun-Su Yuan, MD, PhD, from the Tang Center for Herbal Medicine Research at the University of Chicago, Illinois. Tianqi "could provide a new option for diabetes management, using herbal medicine alone or as an adjuvant to currently used therapies," he noted.
The results are published online January 16 in the Journal of Clinical Endocrinology & Metabolism, and Dr. Yuan said robust data such as these are needed to help promote the use of Chinese herbal medicine by physicians in different countries.
Most significantly, the researchers found that taking Tianqi reduced the risk for diabetes by almost a third (32.1%) compared with placebo, after adjustment for age and gender. The proportion of participants who had normal glucose tolerance after 12 months of receiving either Tianqi or placebo was 63.1% (n=125) and 46.6% (n=89), respectively (P = .001). A total of 36 participants in the Tianqi group (18.18%) and 56 in the placebo group (29.32%) developed diabetes (P = .01).
A Role for Chinese Medicine in Diabetes Prevention?
The findings show that the Chinese herbal medicine was comparable to some pharmaceuticals in reducing progression to type 2 diabetes, say the researchers. For example, the results seen with Tianqi were similar to those found with acarbose, at 25%, and metformin, at 31%.
"Although no direct comparison has been made between Tianqi and antidiabetic prescription drugs, our data indicate that this Chinese herbal medicine had similar effects to metformin," reported Dr. Yuan.
Asked to comment on whether diabetes prevention was regularly practiced in the United States, he remarked that unacceptable adverse effects limited regular use of conventional therapies in the prevention of type 2 diabetes, with reports showing that long-term administration of acarbose or metformin had often been associated with unfavorable gastrointestinal events.
Around 79 million individuals in the United States aged over 20 years have prediabetes, a state in which blood glucose levels are higher than normal but do not meet the diagnostic criteria for type 2 diabetes.
Dr. Yuan added that their data also show that after a period of cessation of the Tianqi treatment, the preventive effects on type 2 diabetes development remained significant. "Moreover, the safety profile of this herbal medicine is very good without obvious adverse effects," he commented.
Chinese Herb Combination and Study Design
The Chinese medicine comprises several herbs that have been shown to lower blood glucose levels after meals. The Tianqi capsule is manufactured by Heilongjiang Baoquan Pharmaceutical and consists of 10 Chinese herbal medicines: Astragali Radix, Coptidis Rhizoma, Trichosanthis Radix, Ligustri Lucidi Fructus, Dendrobii Caulis, Ginseng Radix, Lycii Cortex, Ecliptae Herba, Galla Chinensis, and Corni Fructus. The quality of these herbs and decoction preparation was in accordance with the Chinese Pharmacopoeia, the researchers note.
Dr. Yuan said the key herb in the combination was Huanglian (Coptidis Rhizoma). "The critical component of this herb is berberine, which has been reported to have good antidiabetic effects," he toldMedscape Medical News in an interview. "Huanglian has been used traditionally in Chinese medicine in treating diabetic symptoms."
A total of 420 participants with IGT recruited from 11 research sites in China underwent double-blind randomization to receive either Tianqi (n=210) or a placebo (n=210) for 12 months. Participants had IGT with a 2-hour plasma glucose concentration of 7.8–11.1 mmol/L after a 75-g oral glucose tolerance test and fasting plasma glucose greater than 7.0 mmol/L.
Oral glucose tolerance tests were conducted every 3 months to assess the development of diabetes or restoration to normal glucose tolerance. In addition, all participants received similar lifestyle education.
The primary end point was the conversion of IGT to type 2 diabetes; body weight, body mass index, and adverse effects were monitored.
Need For More Controlled Trials of Chinese Medicinal Herbs
"Although the results of the present study need to be confirmed in future larger clinical trials, Tianqi holds promising potential as an effective and practical means to prevent type 2 diabetes, particularly in places in which herbal medicines are culturally accepted and widely used," say the authors.
They note that treating diabetes with Chinese herbal medicines is popular in China, particularly in rural areas.
"Our encouraging data should initiate further studies, both in China and in the West, to evaluate the role of Chinese herbal medicine in preventing and treating diabetes," said Dr. Yuan. "We are currently conducting several studies in this field."
This work was supported in part by the Ministry of Science and Technology of the People’s Republic of China, National Key Technology R&D Program. The authors have reported no relevant financial relationships.
J Clin Endocrinol Metab. Published online January 16, 2014. Abstract
Friday, January 17, 2014
The Boston Globe (1/16, Kotz) reports a Massachusetts Department of Public Health and University of Massachusetts Medical School study published online in the journal Nicotine and Tobacco Research indicates that particular cigarette manufacturers have increased the nicotine in their product. Researchers found the average cigarette contained 1.65 milligrams of the substance in 1999, but increased 15% to 1.89 milligrams in 2011. Study leader Thomas Land believes the increase may have resulted from redesigning several brands with alterations on filters or product length.
The Springfield (MA) Republican (1/16, Flynn) also quotes Land as saying, “Cigarettes are getting more efficient at delivering nicotine to smokers. This could make it more difficult for a current smoker who is trying to quit, and easier for a young smoker to become addicted.”
Wednesday, January 15, 2014
Bloomberg News (1/14, Edney) reports that “Chelsea Therapeutics International Ltd. won the backing of” an FDA advisory panel “for its drug to prevent sudden drops in blood pressure, a boost for the company’s effort to bring its first product to market.” The piece notes that “many panel members who voted in favor of approval said Chelsea showed the drug works short-term, and that initially is enough for such a rare, devastating disease with no other treatment options.”
Reuters (1/15, Clarke) reports that the drug, Nothera (droxidopa), is for patients with neurogenic orthostatic hypotension (NOH), a rare, chronic type of low blood pressure that is linked with certain neurological disorders such as Parkinson’s disease.